Literature DB >> 2445655

Monoclonal antibodies to human tumor necrosis factors alpha and beta: application for affinity purification, immunoassays, and as structural probes.

T S Bringman1, B B Aggarwal.   

Abstract

Monoclonal antibodies were produced against two structurally related tumor necrosis factors (TNFs), TNF-alpha (previously called tumor necrosis factor) and TNF-beta (previously called lymphotoxin). The potential of these antibodies for the purification of TNFs, the development of specific immunoassays, and for defining the antigenic and functional domains of these cytokines was investigated. None of the monoclonal antibodies cross-reacted with both TNF-alpha and TNF-beta, or reacted with synthetic peptides which represented several of the regions of homology between these cytokines. Neutralizing monoclonal antibodies were utilized as immunoadsorbents to purify recombinant TNF-alpha and TNF-beta from E. coli lysates. TNFs purified by this method were greater than 98 percent pure by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and exhibited specific activities that were the same as TNFs isolated from natural sources using conventional chromatographic techniques. In addition, specific ELISA assays were developed that could detect less than 1 ng/ml of TNF-alpha or TNF-beta, and in contrast to bioassays, could discriminate between these related cytokines.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2445655     DOI: 10.1089/hyb.1987.6.489

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  21 in total

1.  Production of polyclonal antibodies to feline tumor necrosis factor.

Authors:  C M Otto; F Niagro; R A McGraw; C A Rawlings
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

2.  Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus.

Authors:  C O Jacob; Z Fronek; G D Lewis; M Koo; J A Hansen; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

3.  Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin.

Authors:  A Ashkenazi; S A Marsters; D J Capon; S M Chamow; I S Figari; D Pennica; D V Goeddel; M A Palladino; D H Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

Review 4.  Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.

Authors:  Bharat B Aggarwal; Subash C Gupta; Ji Hye Kim
Journal:  Blood       Date:  2011-11-03       Impact factor: 22.113

Review 5.  Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs.

Authors:  Sandhya Jinesh
Journal:  Inflammopharmacology       Date:  2015-02-17       Impact factor: 4.473

Review 6.  Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease.

Authors:  Ioannis Androulakis; Christos Zavos; Panagiotis Christopoulos; George Mastorakos; Maria Gazouli
Journal:  World J Gastroenterol       Date:  2015-12-21       Impact factor: 5.742

Review 7.  Tumor necrosis factor: an update on basic research and clinical applications.

Authors:  M Schleuning; R Munker
Journal:  Klin Wochenschr       Date:  1990-09-03

8.  Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors.

Authors:  A L Asher; J J Mulé; A Kasid; N P Restifo; J C Salo; C M Reichert; G Jaffe; B Fendly; M Kriegler; S A Rosenberg
Journal:  J Immunol       Date:  1991-05-01       Impact factor: 5.422

9.  Tumor necrosis factor alpha and lymphotoxin production in Hodgkin's disease.

Authors:  C Kretschmer; D B Jones; K Morrison; C Schlüter; W Feist; A J Ulmer; J Arnoldi; J Matthes; T Diamantstein; H D Flad
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

10.  Induction of interleukin-2 receptor by tumor necrosis factor alpha on cultured ovarian tumor-associated lymphocytes.

Authors:  C G Ioannides; B Fisk; B Tomasovic; R Pandita; B B Aggarwal; R S Freedman
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.